Optical Tour: Top 10 takeaways from our visits with entrepreneurs on technology development, demand, supply, and competition

Allen Chang
+852-2978-2930 | allen.k.chang@gs.com
Goldman Sachs (Asia) L.L.C.

Verena Jeng
+852-2978-1681 | verena.jeng@gs.com
Goldman Sachs (Asia) L.L.C.

Ting Song
+852-2978-6466 | ting.song@gs.com
Goldman Sachs (Asia) L.L.C.

Yifan Hu
+852-2978-0996 | yifan.hu@gs.com
Goldman Sachs (Asia) L.L.C.

We visited optical companies during the Asia Leader Conference, Semicon Taiwan, and China AI Tour on Aug 31 to Sep 7 in Hong Kong, Taiwan, and Suzhou: **(1) Optical module:** Innolight (300308.SZ / 3308.HK, Buy), Dongshan Precision (002384.SZ, Not Covered), HG Tech (000988.SZ, Not Covered), CIG (6166.HK, Not Covered), Lightelligence (1879.HK, Not Covered), **(2) Photonics IC testing and coupling equipment suppliers:** Robotechnik (300757.SZ, Buy), ASMPT (0522.HK, Neutral), GMT (4573.TWO, Not Covered), Enlitech (7728.TWO, Not Covered), Fittech (6706.TW, Not Covered), **(3) FAU for NPO / CPO:** FOCI (3363.TWO, Buy), **(4) InP epiwafer / CW lasers:** VPEC (2455.TW, Buy), Everbright (688048.SS, Not Covered). We summarize the key takeaways in this report.

Top 10 takeaways

1. Optical module demand outlook: Companies we visited remain positive on optical module demand, driven by AI server racks ramp up, optical module adoption expansion (from scale out to scale up / across), and specification upgrade. On global market demand on 800G and 1.6T, demand could be at 130m to 200m; for the China market, overall demand could also grow at mid double digits to 50m+ units, with the majority 800G and 400G, and 1.6T emerging. Nevertheless, companies we visited with also mentioned that tight raw material supply (e.g. DSP, lasers, PCB) could continue to cap shipments in 2027. The positive tone echoes our positive view on global demand, on which we raised 800G and above optical module demand by 39% / 36% in 2027E / 2028E to 144m / 171m (report link). Supply chain positive tone reflects further upside to our estimates.

2. Optical module competition: Companies we visited see pricing competition remaining healthy, with 800G optical module pricing decline within single digits in 2027, and 1.6T optical module price to sustain at US$700+. Managements highlight that optical module is not a pure assembly but with multiple SKUs and require suppliers' strong R&D and timely development as compared to telecom, the product cycle could shorten to 1-2 years in datacom vs. 5 years in telecom. Supply chain management and mass production capability are also important to win orders, especially under the current tight supply situation and clients' requirements of diversifying production sites under geopolitical tension. Innolight, as the global leader works with supply chain closely, including R&D collaboration, invests directly in their suppliers, and pre-payment and long-term agreements to secure a

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

sustainable supply through cycles.

3. Laser supply: Chinese suppliers are ramping up capacity and capability in 200G EML, supporting the 1.6T optical module ramp up in 2027. Nevertheless, shipment also depends on other raw material supply (e.g. DSP), and customers penetration. Everbright's laser capacity 2027 is EML slightly higher than CW laser, and within the EML majority is for 100G, with the remaining for 200G; Dongshan Precision highlights their 200G EML is already in mass production, while volume is still small currently given the tight supply of DSP; nevertheless, the company also secured 10m supply of DSP in 2027, supporting their lasers and optical modules shipment ramp up. VPEC, global leading InP epiwafer supplier, also sees improving InP substrate supply, with steady export permission from China government, more customers bringing InP substrate, and growing second to fourth suppliers outside of China. VPEC's MOCVD is also in expansion, from current 62 MOCVD to 69 MOCVD by 2Q27, and planning a new production site in 2027.

4. CPO timeline: As a new technology, CPO will naturally take time and could face challenges in the path of commercialization. For example, laser suppliers see thermal challenges for 300mW / 400mW CW lasers in ELS (external laser source), and is working on 100mW+ with PA for NPO first. Optical module suppliers also see strong 3.2T NPO optical engine demand across China and overseas markets. Nevertheless, equipment suppliers remain the earliest beneficiary in CPO, with the strong testing and coupling demand reflecting in equipment suppliers' revenues in mid 2026. For example, Robotechnik 2Q26 revenues were up 172% QoQ, or 141% higher than our estimates. As we highlighted in Sep (report link), we estimate CPO switch at 10k / 92k / 131k units in 2026E-28E.

5. AI spending sustainability: Management highlighted that AI is a revolution, and we are at an early stage of infrastructure spending and application development. It will be a long cycle for the coming 10 to 20 years, and some of their customers are planning beyond 2030. The demand for the coming 2 to 5 years remains very strong and management highlighted their industry enjoys short return on investment, which is around 1 to 2 years. Management highlighted the AI spending is not only building more AI data centers, but also includes technology migration, such as making power consumption more efficient, making data transmission faster, etc., driving the supply chain growth. Compared to the internet bubble in the 2000s, management sees much more transparency between end-customers (demand) and supply chain (supply), as end customers are involved more in supply chain product development and capacity investment, reducing the information gap between demand and supply, and reducing the chance of double booking. Management noted that currently every module they produce is being deployed in data centers, reflecting real demand.

6. Photonics IC scaling up: AI drives data transmission speed and bandwidth requirement, leading to strong demand on Photonics IC, requesting it to catch up Electrical IC automated production and testing ecosystem in 1 to 2 years, while EIC / semiconductors has been developed for decades. The strong demand brings opportunities to tool suppliers, across coupling and testing, which are necessary tools to accelerate PIC production. Robotechnik / FiconTEC describes the number of tools they target to ship in the coming 1 year would be over 50% of what they've shipped in the past 25 years, reflecting the strong demand and orders visibility.

7. Testing - CPO earliest beneficiary: As a new technology, CPO naturally takes time and faces challenges in the path of commercialization; however, we identify testing equipment suppliers as the earliest beneficiaries, considering the expensive final module means multiple testing during the production process is necessary, given the earlier a failure is found, the lower cost a failure is. As a result, companies we visited continue to see Insertion 2 (double-sided wafer-level testing) as necessary, and Robotechnik / FiconTEC launched the new generation in 3Q26, which fully complied with the global leading foundry's communication infrastructure.

8. Testing - shortening time with KGD (know good die) at early stage: To facilitate photonics IC scaling up, not only are more tools needed but better tools, requiring suppliers' strong R&D and execution, delivering continuous specification upgrade. Robotechnik / FiconTEC, as global leaders in PIC testing, aim to shorten the wafer-level testing time by 50-60% next year, and target 4x faster die-level testing next year. Enlitech (7728.TWO, Not Covered) offers NightJar, a hyperspectral image system, revealing AWG (arrayed waveguide grating) optical loss pathways with absolute optical power mapping, allowing customers to KGD at Insertion 1 (PIC wafer testing) or Insertion 0 (PIC wafer early defect screening), saving failure costs.

9. Coupling - automated production becoming necessary in high-speed connection: AI drives optical module towards high speed and high density / bandwidth, driving demand on automated production. GMT (4573.TWO, not covered) showcased dual FA active alignment equipment for 1.6T optical module, which could do the coupling for both Tx and Rx simultaneously, saving 50% of coupling time compared to traditional equipment. FitTech (6706.TW, not covered) has showcased an optical engine assembly system, featuring passive / active alignment and customized development of coupling algorithms, which could be used in multiple products: high-speed optical modules, ELS, OCS, NPO, CPO, SiPh and optical chiplets. ASMPT has showcased MEGA multi-chip bonding solution for complex multi-chip and photonics packaging applications, combining high-precision placement with adhesive dispensing, UV fixation and 3D inspection in one platform.

10. FAU & Laser specification upgrade: With optical networking expanding from scale out to scale up, FAU and laser specification is also migrating. FOCI's FAU in 2026 to be mainly 40 channels (starting in 3Q26) for 3.2T, followed by 80 channels (within 2026) for 6.4T, and 100 channels under R&D, per management. The company's FAU enjoys several customers across fabless, foundry, laser suppliers, etc. FOCI Aug revenues accelerated to +20% MoM (vs. +9% MoM in Jul), reflecting the ramp up of high-end FAU. VPEC's optoelectronics revenues enjoy strong growth on the back of strong CW lasers demand and InP substrate supply getting better. Its InP epiwafer for CW lasers is also migrating from 70mW / 100mW (scale out) to above 100mW (scale up, NPO) and 300mW / 400mW (scale up, CPO), along with expansion from CW lasers to 100G / 200G EML, supporting its growth ahead.

Price Target Risks and Methodology - Zhongji Innolight Co.
Valuation: Our 12-m TPor Innolight A-share of Rmb2,645 is based on 35.6x 2027E P/E, and our 12-m TPor Innolight H-share of HK$3,267 is based on a H-A premium of 13%. We derive our target P/E multiple from the networking peers' trading P/E vs. orward-yearundamentals (NI YoY and OPM). Compared to Innolight's historical trading range, the target multiple reflects our view of its leading market position in high-speed connections and product-mix upgrade toward SiPh optical modules, driving GM expansion. We are Buy rated.

Key downside risks: 1) slower-/worse-than-expected 800G+ optical modules demand; 2) slower/worse-than-expected new optical devices ramp pace; 3) aster-than-expected market share normalizing in 800G+ optical modules; 4) geopolitical risks; and 5) worsening component supply situation to constrain shipment growth.

Price Target Risks and Methodology - VPEC
Valuation: We adopt a discounted P/E method and apply a 22.2x target P/E on VPEC's 2029E EPS, discounting back to 2027E at a COE of 10.5% (beta 1.7x, risk free rate 1.6% and market risk premium at 5.1%), to derive our 12m TP of NT$793. Our target P/E is based on a 0.4x PEG&M ratio derived from the average level of peers in the photonics supply chain.

Key risk: Slower-than-expected SiPh business ramp up; weaker-than-expected microelectronics demand from smartphones clients; IDM offers EPI waer in-house.

Price Target Risks and Methodology - RoboTechnik
Valuation: Our 12-month target price of Rmb796 is based on a 20.7x 2031E P/E, discounted back to 2027E at a COE of 11.3%. Our target multiple is derived from the correlation between consumer electronic peers' PEG&M (2026E P/E to 2027E NI YoY and OPM), with RoboTechnik's 2032E net income at 2% YoY and 2032E OPM at 32%.

Key downside risks: Fiercer-than-expected market competition; lower-than-expected optical connection end demand; worse-than-expected photovoltaic market downcycle.

Valuation: Our 12-month target price of NT$833 is based on a 15.4x 2030E P/E, discounted back to 2027E at a COE of 12.6%. Our target multiple is derived from peers' correlation betweenorward-year trading P/E and earnings growth.

Key downside risks: Fiercer-than-expected market competition, technology migration trends in optical networking, and slower-than-expected capacity ramp-up.

Price target methodology and risks - ASMPT
Valuation methodology: We are Neutral rated on ASMPT with a 12-month target price of HK$177, which is based on a 24.9x 2030E discounted P/E (discounted back to 2027E). Our target P/E is derived from correlation between peers P/E to the sum of NI YoY and OPM.

Key upside/downside risks: 1) customers'aster-/slower-than-expected adoption of Advanced Packaging tools; 2) stronger-/weaker-than-expected demand from automotive customers; and 3) stronger-/weaker-than-expected demandor traditional IC packaging and SMT equipment.

Disclosure Appendix

Reg AC

We, Allen Chang, Verena Jeng, Ting Song and Yifan Hu, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

Contributing Authors: Allen Chang Goldman Sachs (Asia) L.L.C., Verena Jeng Goldman Sachs (Asia) L.L.C., Ting Song Goldman Sachs (Asia) L.L.C., Yifan Hu Goldman Sachs (Asia) L.L.C..

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

Rating and pricing information

ASMPT (Neutral, HK$161.80), FOCI (Buy, NT$681.00), Innolight (A) (Buy, Rmb926.00), Innolight (H) (Buy, HK$1,170.00), RoboTechnik (Buy, Rmb630.00) and VPEC (Buy, NT$515.00)

The rating(s) for ASMPT, Dongshan Precision, FOCI, Innolight (A), Innolight (H), RoboTechnik and VPEC is/are relative to the other companies in its/their coverage universe: AAC, ACM Research, AMEC, ASMPT, AVC, AccoTest, Anji Micro, Asus, Auras, BOE, BYDE, Biren, CR Micro, CXMT, Cambricon, Chenbro, China Mobile (HK), China Telecom, China Tower Corp., China Unicom, Chinasoft Intl, Compal, Desay SV, E Ink, E-Town Semis, EHang, Empyrean, Eoptolink, FOCI, Fositek, Foxconn Industrial Internet, Gigabyte, Gigadevice, Glodon Co., HTC Corp., Hikvision, Hon Hai, Horizon Robotics, Hua Hong, Huace Navigation, Huaqin Co.(A), Huaqin Co.(H), Hwatsing, Iluvatar, InnoScience, Innolight (A), Innolight (H), Inspur, Insta360, Inventec, JCET, Kematek, King Slide, Kingdee, Kingsoft Office, LandMark, Largan, Lenovo, Lingyi, Luxshare (A), Luxshare (H), Maxscend, Meitu, MetaX, Mitac, Montage (A), Montage (H), NAURA, NSIG, Nexchip, OmniVision, Pegatron, Pony AI Inc. (ADR), Pony AI Inc. (H), Quanta, RoboTechnik, Ruijie Networks, SG Micro, SICC, SMIC (A), SMIC (H), SZS, Sangfor, SenseTime, Shengyi Tech, Shennan Circuits, StarPower, Sunny Optical, TFC Optical, Thundersoft, Tongyu Communication, Transsion, UMT, UNIS, VPEC, Vanchip, VeriSilicon, Victory Giant, WNC, WUS, WeRide, Wistron, Wiwynn, YJ Semitech, YOFC, Yonyou, ZTE (A), ZTE (H), iFlytek

Company-specific regulatory disclosures


Compendium report: please see disclosures at https://www.gs.com/research/hedge.html. Disclosures applicable to the companies included in this compendium can be found in the latest relevant published research

Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	Rating Distribution			Investment Banking Relationships		
	Buy	Hold	Sell	Buy	Hold	Sell
Global	50%	34%	16%	65%	59%	43%

As of July 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,104 equity securities. Goldman Sachs
and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold



purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)

Compendium report: please see disclosures at https://www.gs.com/research/hedge.html. Disclosures applicable to the companies included in this compendium can be found in the latest relevant published research

Target price history table(s)

FOCI (3363.TWO)

Date of report	Target price (NT$)	Closing price (NT$)
06-Aug-26	833.00	604.00
06-Jul-26	864.00	574.00

RoboTechnik (300757.SZ)

Date of report	Target price (Rmb)	Closing price (Rmb)
28-Aug-26	796.00	536.70
29-May-26	788.00	639.30
16-Apr-26	688.00	496.46

Innolight (H) (3308.HK)

Date of report	Target price (HK$)	Closing price (HK$)
06-Sep-26	3,267.00	1,006.00

ASMPT (0522.HK)

Date of report	Target price (HK$)	Closing price (HK$)
29-Jul-26	177.00	136.90
13-Jul-26	206.00	185.40
22-Apr-26	118.30	152.20
05-Mar-26	103.90	112.40
30-Jan-26	90.70	103.90
02-Oct-25	79.00	85.00
23-Jul-25	69.00	63.20
01-May-25	60.20	52.20
06-Apr-25	61.00	53.65
11-Mar-25	65.00	58.25
26-Feb-25	86.00	64.05
01-Jan-25	100.00	74.90
01-Nov-24	108.00	83.75
25-Jul-24	117.00	78.70
24-Apr-24	136.12	102.30
12-Mar-24	124.01	108.30
29-Feb-24	109.16	95.95
12-Feb-24	109.16	85.70
03-Dec-23	105.00	79.05
21-Sep-23	94.00	66.85

VPEC (2455.TW)

Date of report	Target price (NT$)	Closing price (NT$)
07-Sep-26	793.00	500.00
30-Jul-26	505.00	265.50
17-May-26	504.00	358.50
02-Mar-26	267.00	239.00
07-Oct-25	233.00	163.00
28-Sep-25	218.00	154.00
17-Sep-25	212.00	160.50
20-Jul-25	186.00	136.00
24-Apr-25	189.50	92.40
06-Apr-25	222.70	115.50
13-Feb-25	233.00	156.50

Innolight (A) (300308.SZ)

Date of report	Target price (Rmb)	Closing price (Rmb)
06-Sep-26	2,645.00	814.00
17-Jul-26	2,581.00	979.46
16-Apr-26	1,187.00	809.61
09-Mar-26	791.00	525.99
20-Nov-25	762.00	492.00
14-Oct-25	470.00	346.10
08-Sep-25	442.00	369.99
26-Aug-25	392.00	314.00
16-Jul-25	182.00	170.76
07-Jul-25	160.00	135.15
13-May-25	115.00	96.43
22-Apr-25	105.00	80.07
07-Apr-25	115.00	75.10
25-Mar-25	170.00	102.00
03-Mar-25	185.00	102.77
27-Jan-25	215.00	114.82
16-Jan-25	230.00	119.49
05-Nov-24	240.00	148.29
22-Oct-24	215.00	170.00
09-Oct-24	230.00	166.40
26-Aug-24	201.00	114.34

VPEC (2455.TW)

Date of report	Target price (NT$)	Closing price (NT$)

Innolight (A) (300308.SZ)

Date of report	Target price (Rmb)	Closing price (Rmb)
17-Jun-24	200.00	142.51
05-Jun-24	230.00	119.26
06-May-24	227.00	130.87
10-Apr-24	200.00	113.93
05-Mar-24	192.00	120.83
23-Feb-24	175.00	105.52
28-Jan-24	170.00	82.83
10-Dec-23	168.00	83.93
24-Oct-23	167.00	68.43

Price targets shown in table(s) are unadjusted for corporate actions.

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; registered market maker. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading in securities covered by the analysts.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details, a copy of the annual compliance audit report and other relevant information and disclosures can be found at this link: https://www.goldmansachs.com/worldwide/india/research-analyst. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have

been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at https://www.gs.com/disclosures/europeanpolicy.html which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at https://www.gs.com/research/hedge.html.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (https://www.sipc.org).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such

trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, make a market or act as liquidity provider in, and buy or sell, any securities, derivatives, or other financial instruments referred to in this research (including any financial instruments issued by the companies referred to herein), unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at https://www.theocc.com/about/publications/character-risks.jsp and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to https://research.gs.com.

Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY 10282.

© 2026 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.